Research Title: Anecortave Acetate Risk-Reduction Trial (AART)
Principal Investigator: Atul Sharma, M.D.
Description: A 48-month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Start Date: March 2006
Project Personnel: Leslie Marcus, CCRC
Location(s): Riverdale; 155 Medical Way, Suite E, Riverdale, GA 30274